Theravance, Inc. (NASDAQ:THRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.

Recs

0
Player Avatar withoutlimits (84.28) Submitted: 9/30/2010 7:50:58 PM : Underperform Start Price: $20.17 THRX Score: +5.71

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

Featured Broker Partners


Advertisement